VAXCYTE, INC. Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale
VAXCYTE, INC. (PCVX) reported Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale of $739.10 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities · last filed 2026-08-05
- VAXCYTE, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2026-06-30 was $398.46M, a 1.01% increase year-over-year.
- VAXCYTE, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2026-03-31 was $340.63M, a 22.32% decline year-over-year.
- VAXCYTE, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2025-12-31 was $347.97M, a 32.03% increase year-over-year.
- VAXCYTE, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2025-09-30 was $350.20M, a 6.87% increase year-over-year.
- VAXCYTE, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2025 was $1.53B, a 35.11% increase from fiscal 2024.
- VAXCYTE, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2024 was $1.13B, a 85.21% increase from fiscal 2023.
- VAXCYTE, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2023 was $611.88M, a 262.72% increase from fiscal 2022.
- VAXCYTE, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2022 was $168.69M, a 67.85% increase from fiscal 2021.
| Period end | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 3 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 6 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 9 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2026-06-30 | $398.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $739.10M 10-Q · filed 2026-08-05 | $1.09B derived: sum of 3 quarters · filed 2026-08-05 | $1.44B derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $340.63M 10-Q · filed 2026-05-06 | $688.60M derived: sum of 2 quarters · filed 2026-05-06 | $1.04B derived: sum of 3 quarters · filed 2026-05-06 | $1.43B derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $347.97M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $698.17M derived: sum of 2 quarters · filed 2026-02-24 | $1.09B derived: sum of 3 quarters · filed 2026-08-05 | $1.53B 10-K · filed 2026-02-24 |
| 2025-09-30 | $350.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $744.68M derived: sum of 2 quarters · filed 2026-08-05 | $1.18B 10-Q · filed 2025-11-04 | $1.45B derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $394.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $832.96M 10-Q · filed 2026-08-05 | $1.10B derived: sum of 3 quarters · filed 2026-08-05 | $1.42B derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $438.49M 10-Q · filed 2026-05-06 | $702.03M derived: sum of 2 quarters · filed 2026-05-06 | $1.03B derived: sum of 3 quarters · filed 2026-05-06 | $1.33B derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $263.55M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $591.25M derived: sum of 2 quarters · filed 2026-02-24 | $890.92M derived: sum of 3 quarters · filed 2026-02-24 | $1.13B 10-K · filed 2026-02-24 |
| 2024-09-30 | $327.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $627.37M derived: sum of 2 quarters · filed 2025-11-04 | $869.69M 10-Q · filed 2025-11-04 | $1.11B derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $299.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $541.99M 10-Q · filed 2025-08-06 | $784.95M derived: sum of 3 quarters · filed 2026-02-24 | $1.02B derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $242.32M 10-Q · filed 2025-05-07 | $485.27M derived: sum of 2 quarters · filed 2026-02-24 | $718.20M derived: sum of 3 quarters · filed 2026-02-24 | $814.03M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $242.96M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $475.88M derived: sum of 2 quarters · filed 2026-02-24 | $571.72M derived: sum of 3 quarters · filed 2026-02-24 | $611.88M 10-K · filed 2026-02-24 |
| 2023-09-30 | $232.92M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $328.76M derived: sum of 2 quarters · filed 2024-11-05 | $368.92M 10-Q · filed 2024-11-05 | $401.42M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | $95.84M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $136.00M 10-Q · filed 2024-08-06 | $168.50M derived: sum of 3 quarters · filed 2025-02-25 | $214.64M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | $40.16M 10-Q · filed 2024-05-08 | $72.66M derived: sum of 2 quarters · filed 2025-02-25 | $118.80M derived: sum of 3 quarters · filed 2025-02-25 | $149.30M derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | $32.50M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $78.64M derived: sum of 2 quarters · filed 2025-02-25 | $109.14M derived: sum of 3 quarters · filed 2025-02-25 | $168.69M 10-K · filed 2025-02-25 |
| 2022-09-30 | $46.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $76.64M derived: sum of 2 quarters · filed 2023-11-06 | $136.19M 10-Q · filed 2023-11-06 | $178.69M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $30.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $90.05M 10-Q · filed 2023-08-08 | $132.55M derived: sum of 3 quarters · filed 2024-02-27 | $169.55M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $59.55M 10-Q · filed 2023-05-08 | $102.05M derived: sum of 2 quarters · filed 2024-02-27 | $139.05M derived: sum of 3 quarters · filed 2024-02-27 | |
| 2021-12-31 | $42.50M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $79.50M derived: sum of 2 quarters · filed 2024-02-27 | $100.50M 10-K · filed 2024-02-27 | |
| 2021-09-30 | $37.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $58.00M 10-Q · filed 2022-11-07 | ||
| 2021-06-30 | $21.00M 10-Q · filed 2022-08-08 | |||
| 2020-12-31 | $0.00 10-K · filed 2023-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |